Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when DNLI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsDenali to sell FDA Priority Review Voucher for $195M cash
Filed June 18, 2026 · Period ending June 12, 2026 · ~1 min read
Key Changes
-
high
Denali agreed to sell its Rare Pediatric Disease Priority Review Voucher for $195 million in cash, awarded when the FDA approved its Hunter syndrome drug in March 2026.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
medium
The sale remains subject to Hart-Scott-Rodino antitrust clearance; cash will be received at closing once regulatory waiting period expires.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
Summary
Denali Therapeutics is monetizing a valuable regulatory asset it earned from its first FDA approval. The company received a Priority Review Voucher when the FDA approved AVLAYAH for Hunter syndrome in March 2026, and has now found a buyer willing to pay $195 million cash for it.
These vouchers allow the holder to accelerate FDA review of a future drug application from ten months to six months, making them attractive to companies with late-stage pipeline assets. The transaction is pending routine antitrust clearance under Hart-Scott-Rodino rules, which typically takes 30 days unless the government requests additional information.
For retail investors, this represents a significant non-dilutive cash infusion that strengthens Denali's balance sheet without issuing new shares. The company can deploy this capital toward its ongoing neurodegenerative disease programs. Watch for the closing announcement in the next 30-60 days, which will confirm the cash hit the balance sheet and may be accompanied by management commentary on capital allocation priorities.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 12, 2026, Denali Therapeutics Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Transfer Agreement”), pursuant to which the Company agreed to sell its Rare Pediatric Disease Priority Review Voucher (“PRV”). The Company was awarded the voucher under a U.S. Food and Drug Administration (“FDA”) program intended to encourage the development of certain rare pediatric disease product applications. The Company received the PRV when AVLAYAHTM (tividenofusp alfa) was approved by the FDA for the treatment of Hunter syndrome (mucopolysaccharidosis type II; MPS II) in March 2026. Pursuant to the PRV Transfer Agreement, the buyer agreed to pay the Company $195 million, payable in cash, upon the closing of the sale.
Denali entered into an agreement to sell a Priority Review Voucher it received when the FDA approved its Hunter syndrome drug in March 2026. The buyer will pay $195 million in cash at closing. This voucher allows the buyer to accelerate FDA review of a future drug application, and such vouchers are tradable assets that biotech companies often monetize.
Added in current filing · verify on EDGAR →
The transaction remains subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
The $195 million sale has not yet closed. It requires Hart-Scott-Rodino antitrust clearance, a standard regulatory waiting period for transactions above certain dollar thresholds. Until HSR clearance is obtained, the company has not received the cash and the deal could theoretically be delayed or blocked, though such outcomes are uncommon for PRV sales.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 18, 2026 · How we verify